JFLB(002762)2021-10-29 16:00Financial Performance - The company's revenue for Q3 2021 was ¥78,927,540.18, a decrease of 11.63% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥10,072,006.76, representing a decline of 179.00% year-on-year[3]. - The basic earnings per share for Q3 2021 was -¥0.03, down 175.00% from the previous year[3]. - Net profit for Q3 2021 was CNY 6,482,188.15, down from CNY 23,053,007.13 in Q3 2020, indicating a decline of about 71.8%[21]. - The company's operating profit for Q3 2021 was CNY 4,318,089.40, significantly lower than CNY 28,002,609.22 in the same period last year, reflecting a decrease of approximately 84.6%[21]. - The company reported a total revenue from sales of goods and services of CNY 211,534,596.30 in Q3 2021, compared to CNY 225,541,813.06 in Q3 2020[24]. - Basic and diluted earnings per share for Q3 2021 were both CNY 0.02, down from CNY 0.07 in Q3 2020, reflecting a decrease of approximately 71.4%[22]. Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,062,505,433.89, a decrease of 3.65% from the end of the previous year[3]. - Total assets decreased to CNY 1,062,505,433.89 from CNY 1,102,746,528.91[18]. - Total liabilities decreased to CNY 86,604,166.81 from CNY 112,085,949.98[18]. - The company's total liabilities decreased by 100% in short-term borrowings, as it repaid all due short-term loans[10]. - Total equity attributable to shareholders was CNY 973,895,557.07, down from CNY 988,533,210.95[18]. Cash Flow - Cash flow from operating activities showed a negative net amount of -¥16,115,510.56, a decline of 144.96% compared to the previous year[3]. - Cash flow from operating activities showed a net outflow of CNY -16,115,510.56 in Q3 2021, compared to a net inflow of CNY 35,843,645.81 in Q3 2020[24]. - Cash and cash equivalents as of September 30, 2021, amounted to CNY 98,648,840.25, down from CNY 175,247,937.16[16]. - Cash and cash equivalents at the end of Q3 2021 were CNY 88,044,601.18, down from CNY 131,150,130.64 at the end of Q3 2020, a decrease of about 32.9%[25]. - The net cash outflow from investing activities was CNY -19,024,841.35 in Q3 2021, compared to CNY -34,843,423.34 in Q3 2020, showing an improvement in cash flow[25]. Investments and Subsidies - The company recognized an investment loss of ¥975,050 from its equity method accounting for the investment in Mierle Er乳业[8]. - The company recorded investment losses of CNY -1,037,543.22 in Q3 2021, contrasting with investment income of CNY 9,375,264.31 in Q3 2020[21]. - The company received government subsidies amounting to ¥500,000 during the reporting period, contributing to other income[10]. - The company reported a significant increase in long-term equity investments, which rose by 391.10% to ¥263,190,419.19 due to investments in the Hanfei Medical Beauty project[9]. Shareholder Information - The company reported a total of 45,339 common shareholders at the end of the reporting period[13]. - The top two shareholders, Lin Haoliang and Lin Ruowen, hold 30.29% and 27.82% of shares, respectively[13]. Research and Development - Research and development expenses for Q3 2021 were CNY 11,032,931.74, slightly up from CNY 10,850,478.07 in Q3 2020, indicating an increase of about 1.7%[21]. Market Strategy - The company plans to continue its market expansion and product development strategies, focusing on enhancing its product offerings in the maternal and infant goods sector[8]. - The company has not disclosed any new product developments or market expansion strategies in the current report[14].